Andrew Erickson

Dr. Andrew Erickson


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in European Urology Focus
Verified
Journal Article
Open access
ULUtku Lokman
Utku Lokman
AEAndrew Erickson
Andrew Erickson
HVHanna Vasarainen
Hanna Vasarainen
ARAntti Rannikko
Antti Rannikko
TMTuomas K. Mirtti
Tuomas K. Mirtti
Active surveillance (AS) is an option for men with low-risk prostate cancer (PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression and survival. To study the role of ERG and PTEN status in the Prostate Cancer Research International: Active Surveillance (PRIAS) trial diagnostic biopsies (DBxs) in predicting surveillance discontinuation and adverse surgical findings in subsequent radical prostatectomy (RP). A total of 231 patients were recruited to the PRIAS between 2007 and 2013 in Helsinki. DBx tissue for immunohistochemistry (IHC) was available from 190 patients. Tissue microarrays (TMAs) were constructed from 57 specimens of subsequent RPs. DBxs containing grade group (GG) 1 PCa and RP TMA sections were stained with ERG and PTEN antibodies, and scored as either negative or positive. Outcomes were followed up by biopsy GG upgrade (GG ≥ 2) and protocol-based treatment change, as well as adverse findings in RP (GG ≥ 3 or pathological stage≥3). Clinical variables and biomarker status in DBx were correlated in Cox regression analysis and cumulative survival in Kaplan-Meier analysis, and finally, Gray's competing risk analysis was performed and nonprotocol-based discontinuation was considered as a competing event. In both uni- and multivariate Cox regression analyses, only the number of positive cores in the DBx, the number of rebiopsy sessions, and PTEN status at diagnosis were significantly associated with rebiopsy GG upgrade, treatment change, and adverse histopathology in RP. In Kaplan-Meier analysis, PTEN loss was associated with a shorter time to GG upgrade and treatment change. Patients with PTEN loss had a higher probability for protocol-based discontinuation but not for competing risk factors compared with patients with intact PTEN. Biopsy ERG status was concordant with RP TMA ERG status, while PTEN was not. Limitations include a retrospective analysis of prospective cohort data. PTEN status at diagnosis is a potential biomarker for identifying patients with PCa on AS with a high risk for progression or adverse findings on subsequent RP. A simple diagnostic biopsy-based analysis of PTEN status may help identify patients with high risk for prostate cancer progression.

28 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ECEduard Chelebian
Eduard Chelebian
CAChristophe Avenel
Christophe Avenel
KKKimmo Kartasalo
Kimmo Kartasalo
MMMaja Marklund
Maja Marklund
ATAnna Tanoglidi
Anna Tanoglidi
CWCarolina Wählby
Carolina Wählby
Prostate cancer is a common cancer type in men, yet some of its traits are still under-explored. One reason for this is high molecular and morphological heterogeneity. The purpose of this study was to develop a method to gain new insights into the connection between morphological changes and underlying molecular patterns. We used artificial intelligence (AI) to analyze the morphology of seven hematoxylin and eosin (H&E)-stained prostatectomy slides from a patient with multi-focal prostate cancer. We also paired the slides with spatially resolved expression for thousands of genes obtained by a novel spatial transcriptomics (ST) technique. As both spaces are highly dimensional, we focused on dimensionality reduction before seeking associations between them. Consequently, we extracted morphological features from H&E images using an ensemble of pre-trained convolutional neural networks and proposed a workflow for dimensionality reduction. To summarize the ST data into genetic profiles, we used a previously proposed factor analysis. We found that the regions were automatically defined, outlined by unsupervised clustering, associated with independent manual annotations, in some cases, finding further relevant subdivisions. The morphological patterns were also correlated with molecular profiles and could predict the spatial variation of individual genes. This novel approach enables flexible unsupervised studies relating morphological and genetic heterogeneity using AI to be carried out.

5 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KSKonrad Sopyllo
Konrad Sopyllo
AEAndrew Erickson
Andrew Erickson
TMTuomas K. Mirtti
Tuomas K. Mirtti
Gleason grading remains the strongest prognostic parameter in localized prostate adenocarcinoma. We have here outlined the evolution and contemporary practices in pathological evaluation of prostate tissue samples for Gleason score and Grade group. The state of more observer-independent grading methods with the aid of artificial intelligence is also reviewed. Additionally, we conducted a systematic review of biomarkers that hold promise in adding independent prognostic or predictive value on top of clinical parameters, Grade group and PSA. We especially focused on hard end points during the follow-up, i.e., occurrence of metastasis, disease-specific mortality and overall mortality. In peripheral blood, biopsy-detected prostate cancer or in surgical specimens, we can conclude that there are more than sixty biomarkers that have been shown to have independent prognostic significance when adjusted to conventional risk assessment or grouping. Our search brought up some known putative markers and panels, as expected. Also, the synthesis in the systematic review indicated markers that ought to be further studied as part of prospective trials and in well characterized patient cohorts in order to increase the resolution of the current clinico-pathological prognostic factors.

9 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KSKevin Sandeman
Kevin Sandeman
JEJuho T Eineluoto
Juho T Eineluoto
JPJoona Pohjonen
Joona Pohjonen
AEAndrew Erickson
Andrew Erickson
TKTuomas P Kilpeläinen
Tuomas P Kilpeläinen
ARAntti Rannikko
Antti Rannikko
To determine the added value of preoperative prostate multiparametric MRI (mpMRI) supplementary to clinical variables and their role in predicting post prostatectomy adverse findings and biochemically recurrent cancer (BCR). All consecutive patients treated at HUS Helsinki University Hospital with robot assisted radical prostatectomy (RALP) between 2014 and 2015 were included in the analysis. The mpMRI data, clinical variables, histopathological characteristics, and follow-up information were collected. Study end-points were adverse RALP findings: extraprostatic extension, seminal vesicle invasion, lymph node involvement, and BCR. The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram, Cancer of the Prostate Risk Assessment (CAPRA) score and the Partin score were combined with any adverse findings at mpMRI. Predictive accuracy for adverse RALP findings by the regression models was estimated before and after the addition of MRI results. Logistic regression, area under curve (AUC), decision curve analyses, Kaplan-Meier survival curves and Cox proportional hazard models were used. Preoperative mpMRI data from 387 patients were available for analysis. Clinical variables alone, MSKCC nomogram or Partin tables were outperformed by models with mpMRI for the prediction of any adverse finding at RP. AUC for clinical parameters versus clinical parameters and mpMRI variables were 0.77 versus 0.82 for any adverse finding. For MSKCC nomogram versus MSKCC nomogram and mpMRI variables the AUCs were 0.71 and 0.78 for any adverse finding. For Partin tables versus Partin tables and mpMRI variables the AUCs were 0.62 and 0.73 for any adverse finding. In survival analysis, mpMRI-projected adverse RP findings stratify CAPRA and MSKCC high-risk patients into groups with distinct probability for BCR. Preoperative mpMRI improves the predictive value of commonly used clinical variables for pathological stage at RP and time to BCR. mpMRI is available for risk stratification prebiopsy, and should be considered as additional source of information to the standard predictive nomograms.

4 May 2023 in International Journal of Cancer
Verified
Journal Article
Open access
TLTimo‐Pekka K. Lehto
Timo‐Pekka K. Lehto
RKRuusu‐Maaria Kovanen
Ruusu‐Maaria Kovanen
SLSusanna Lintula
Susanna Lintula
AMAdrian Malén
Adrian Malén
CSCarolin Stürenberg
Carolin Stürenberg
HKHannu Koistinen
Hannu Koistinen
We aimed to study mRNA levels and prognostic impact of all 15 human kallikrein‐related peptidases ( KLK s) and their targets, proteinase‐activated receptors ( PAR s), in surgically treated prostate cancer (PCa). Seventy‐nine patients with localized grade group 2‐4 PCas represented aggressive cases, based on metastatic progression during median follow‐up of 11 years. Eighty‐six patients with similar baseline characteristics, but no metastasis during follow‐up, were assigned as controls. Transcript counts were detected with nCounter technology. KLK12 protein expression was investigated with immunohistochemistry. The effects of KLK12 and KLK15 were studied in LNCaP cells using RNA interference. KLK3 , ‐ 2 , ‐ 4 , ‐ 11 , ‐ 15 , ‐ 10 and ‐ 12 mRNA, in decreasing order, were expressed over limit of detection (LOD). The expression of KLK2 , ‐ 3 , ‐ 4 and ‐ 15 was decreased and KLK12 increased in aggressive cancers, compared to controls ( P < .05). Low KLK2 , ‐ 3 and ‐ 15 expression was associated with short metastasis‐free survival ( P < .05) in Kaplan‐Meier analysis. PAR1 and ‐ 2 were expressed over LOD, and PAR1 expression was higher, and PAR2 lower, in aggressive cases than controls. Together, KLKs and PARs improved classification of metastatic and lethal disease over grade, pathological stage and prostate‐specific antigen combined, in random forest analyses. Strong KLK12 immunohistochemical staining was associated with short metastasis‐free and PCa‐specific survival in Kaplan‐Meier analysis ( P < .05). Knock‐down of KLK15 reduced colony formation of LNCaP cells grown on Matrigel basement membrane preparation. These results support the involvement of several KLKs in PCa progression, highlighting, that they may serve as prognostic PCa biomarkers.

18 March 2021 in The Prostate
Verified
Journal Article
Open access
PDF file
TLTimo‐Pekka K. Lehto
Timo‐Pekka K. Lehto
CSCarolin Stürenberg
Carolin Stürenberg
AMAdrian Malén
Adrian Malén
AEAndrew Erickson
Andrew Erickson
HKHannu Koistinen
Hannu Koistinen
TMTuomas K. Mirtti
Tuomas K. Mirtti
Background: Improved prognostication is needed to minimize overtreatment in grade group (GG) 2–4 prostate cancer. Our aim was to determine, at messenger RNA (mRNA) level, the performance of the genes in the commercial panels Decipher, Oncotype DX, Prolaris, and mutational panel MSK‐IMPACT to predict metastasis‐free and prostate cancer‐specific death (PCSD) in patients with GG 2–4 prostate cancer at radical prostatectomy.Methods: The retrospective cohort consisted of GG 2–4 patients treated with radical prostatectomy (median follow‐up 10.4 years). Seventy‐six cases with postoperative metastasis or PCSD and 84 controls with similar clinical baseline risk, but without progression, were analyzed. Index lesion mRNA transcripts were analyzed using NanoString technology. Random forest models were trained using panel gene sets to predict clinical endpoints and area under the curve (AUC), sensitivity, specificity, Youden index, and number needed to diagnose (NND) was measured. Survival probability was assessed with Kaplan–Meier estimator.Results: All gene sets outperformed clinical parameters and predicted metastasis‐free and prostate cancer‐specific survival. However, there were significant differences between the panels. In metastasis prediction, the genes in Oncotype DX had inferior performance (area under the curve [AUC] = 0.65) compared to other panels (AUC = 0.73–0.74). Decipher, MSK‐IMPACT and Prolaris showed similar NND (2.83–3.12) with Oncotype DX having highest NND (4.79). In PCSD prediction, the Prolaris gene set performed worse (AUC = 0.66) than MSK‐IMPACT or Decipher (AUC = 0.72). Oncotype DX performed similarly to other panels (AUC = 0.69, p > .05). Oncotype DX demonstrated lowest NND (2.79) compared to other panels (4.22–5.66).Conclusion: Transcript analysis of genes included in commercial panels is feasible in survival prediction of GG 2‐4 patients after radical prostatectomy and may aid in clinical decision making. There were significant differences between the panels, and overall stronger predictive gene sets are needed. Prospective investigation is warranted in biopsy materials.